ALBIREO PHARMA, INC. (NASDAQ:BIOD) Files An 8-K Other Events
Item8.01
| Other Events. |
On December21, 2016, Albireo Pharma, Inc. (the Company) updated
its corporate presentation, which the Company expects to present
from time to time and which may be distributed by the Company in
hardcopy or electronic form. The updates include preliminary data
from the five cohorts completed to date in the Companys ongoing
open label, Phase 2 clinical trial designed to evaluate the
efficacy and safety of A4250 in children with chronic
cholestasis.
A copy of the Companys updated corporate presentation is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 99.1 | Corporate presentation dated December21, 2016 |
1
About ALBIREO PHARMA, INC. (NASDAQ:BIOD)
Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Its clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. Its pipeline includes A4250, A3384 and Elobixibat. The Company is developing A4250 as a treatment for pediatric orphan cholestatic liver diseases, such as progressive familial intrahepatic cholestasis (PFIC). The Company is developing A3384 for the treatment of bile acid malabsorption (BAM) disease. The Company is also developing Elobixibat as a treatment for chronic idiopathic constipation (CIC). A4250 and Elobixibat are selective inhibitors of the ileal bile acid transporter (IBAT). The Company has completed a Phase II clinical trial of a prototype of A3384 in over 19 subjects with BAM. ALBIREO PHARMA, INC. (NASDAQ:BIOD) Recent Trading Information
ALBIREO PHARMA, INC. (NASDAQ:BIOD) closed its last trading session 00.00 at 19.46 with 2,338,156 shares trading hands.